$Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study$

Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study

Brentuximab vedotin was approved for adult patients with CD30-expressing cutaneous T-cell lymphoma treated with prior systemic therapy based on improved response rates and progression-free survival with brentuximab vedotin (1.8 mg/kg once every 3 weeks; ≤16 cycles) versus physician's choice (me...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European journal of cancer (1990) 2020-07, Vol.133, p.120-130
Hauptverfasser:	Dummer, Reinhard, Prince, Henry M., Whittaker, Sean, Horwitz, Steven M., Kim, Youn H., Scarisbrick, Julia, Quaglino, Pietro, Zinzani, Pier Luigi, Wolter, Pascal, Eradat, Herbert, Pinter-Brown, Lauren, Sanches, Jose A., Ortiz-Romero, Pablo L., Akilov, Oleg E., Geskin, Larisa, Huen, Auris, Walewski, Jan, Wang, Yinghui, Lisano, Julie, Richhariya, Akshara, Feliciano, Joseph, Zhu, Yanyan, Bunn, Veronica, Little, Meredith, Zagadailov, Erin, Dalal, Mehul R., Duvic, Madeleine
Format:	Artikel
Sprache:	eng
Schlagworte:	Brentuximab vedotin CD30 CD30 antigen Clinical trial Confidence intervals Cutaneous T-cell lymphoma Domains Lymphocytes T Lymphoma Measurement methods Methotrexate Monoclonal antibodies Peripheral neuropathy Phase III Quality of life Reduction T-cell lymphoma Targeted cancer therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!